AMAdeline Melard

Adeline Melard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adeline Melard has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Constitutive natural killer cell features associated with post-treatment control of SIV infection in the pVISCONTI study

    by Anaïs Chapel, Luis Romero-Martín, Caroline Passaes, Valérie Monceaux, Stevenn Volant, Delphine Desjardins, Adeline Melard, Annie David, Nathalie Dereuddre-Bosquet, Christine Rouzioux, et al.

    Post-treatment HIV controllers (PTC) offer a unique opportunity to uncover the determinants of durable remission after antiretroviral therapy (ART) interruption. Here, using six PTC and six post-treatment non-controllers from the pVISCONTI study in cynomolgus macaques, we identify associations between Natural Killer (NK) cell subsets and outcomes following ART interruption. NKG2Ahigh NK cells lacking NKp30/NKp46 (NKG2AhighNKp30-NKp46-), shaped by the MHC backgrounds of the animals, were linked to improved post-treatment control; this NK subset displayed tissue-homing potential and preserved functionality despite infection, characterized by cytokine production and degranulation. Conversely, NKG2AlowNKp30 + NKp46+ NK cells exhibited reduced cytotoxic potential and elevated IL-10/IL-17A production, and their pre-infection levels were associated with higher viremia and larger viral reservoirs after ART interruption. Our study suggests that constitutive NK cell features, preserved by early ART initiation, may provide a favorable immune environment for post-treatment control. Our findings identify the NKG2A axis as a potential target to improve outcomes after ART interruption


  • Open Access

    Identification of constitutive NK cell features associated with post-treatment control of SIV infection. The pVISCONTI study

    by Asier Saez-Cirion, Anais Chapel, Luis Romero-Martin, Caroline Passaes, Valérie Monceaux, Stevenn Volant, Delphine Desjardins, Adeline Melard, Annie David, Nathalie Dereuddre-Bosquet, et al.

    Post-treatment HIV controllers (PTC) offer a unique opportunity to uncover the determinants of durable remission after antiretroviral therapy (ART) interruption. Early ART initiation has been shown to favor this outcome, but the underlying immune mechanisms remain unclear. Recent reports suggest that natural killer (NK) cells may play a key role in post-treatment control of infection; however, a direct association with specific NK cell features has not been firmly established. We used a recently reported model of post-treatment control of SIVmac251 infection in Cynomolgus macaques (the pVISCONTI study) to analyze the constitutive and infection-induced characteristics of NK cells and their association with post-treatment viral control. Studying six PTC and six post-treatment non-controllers, we identified two NK cell subsets differing in the expression of NKG2A, NKp30, and NKp46, and which abundance prior to infection showed opposite associations with the outcome after ART interruption. NKG2Ahigh NK cells lacking NKp30/NKp46 (NKG2AhighNKp30-NKp46-), shaped by the MHC background of the animals, were linked to improved post-treatment control. This subset displayed tissue-homing potential and preserved functionality despite infection, characterized by cytokine production and degranulation. Conversely, NKG2AlowNKp30+NKp46+ NK cells exhibited reduced cytotoxicity and elevated IL-10/IL-17A production, and their pre-infection levels were associated with higher viremia and larger viral reservoirs after ART interruption. Our study indicates that constitutive NK cell features, preserved by early ART initiation, may provide a favorable immune environment for post-treatment control. These findings further identify the NKG2A axis as a potential target to improve outcomes after ART interruption.

  • Open Access

    Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption

    by Caroline Charre, Adeline Melard, Antoine Chaillon, Elise Gardiennet, Delphine Desjardins, Caroline Passaes, Antoine Millet, Marine Fillion, Nastasia Dimant, Valérie Monceaux, et al.

    Mechanisms underlying durable control of HIV after antiretroviral therapy interruption remain poorly understood. Here we provide a comprehensive longitudinal analysis in a non-human primate model of post-treatment control using SIVmac251-infected male cynomolgus macaques (pVISCONTI study). Controllers exhibit lower levels of SIV DNA, intact proviruses, transcriptional activity, and viral evolution compared to non-controllers in blood and tissues long after therapy interruption. Before interruption, controllers already have fewer intact proviruses in lymph nodes, and this difference persists in blood shortly after interruption, prior to viral rebound. Intact provirus levels in lymph nodes before interruption negatively correlate with CD8⁺ T-cell capacity to suppress SIV and reflect rebound magnitude. The study demonstrates that markers of post-treatment control are detectable in lymph nodes before therapy interruption and in blood shortly after, and suggests that host immune responses may shape intact provirus profiles during treatment.


  • Open Access

    Maintenance of intestinal CX3CR1+ macrophage homeostasis defines post-treatment control in SIV-infected macaques

    by Stéphane Hua, Keltouma Benmeziane, Delphine Desjardins, Nastasia Dimant, Marco Leonec, Laetitia Bossevot, Julien Lemaitre, Adeline Mélard, Francis Relouzat, VérOnique Avettand-Fenoël, et al.

    Achieving durable viral remission without antiretroviral therapy (ART) remains a central challenge in HIV-1 cure research. Using a pathogenic SIV model in male cynomolgus macaques, we investigated mucosal and systemic immune features associated with post-treatment control (PTC). Chronic SIV infection disrupts intestinal macrophage homeostasis, skewing the compartment toward a CX3CR1 low inflammatory phenotype marked by increased expression of costimulatory and homing markers. This polarization is associated with mucosal CD4 + T cell depletion, elevated neutrophil activation, and systemic cytokine induction. Non-controllers exhibit a similar inflammatory profile. In contrast, PTCs maintain CX3CR1 high macrophages, preserve regulatory CD4 + T cells, and exhibit attenuated mucosal and systemic immune activation, resembling uninfected animals. CX3CR1 high macrophage abundance inversely correlates with viral burden, T cell activation, and pro-inflammatory cytokines, suggesting a potential role in post-treatment control. These findings identify CX3CR1-expressing intestinal macrophages as a potential biomarker of mucosal immune regulation and highlight their relevance as targets in HIV cure strategies.


  • Open Access

    HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir

    by Gilbert Mchantaf, Adeline Melard, Kévin Da Silva, Elise Gardiennet, Antoine Chaillon, Bénédicte Lefebvre, Jade Ghosn, Olivier Robineau, Jean-Paul Viard, Lucie Adoux, et al.

    Background Relatively few studies have investigated HIV-1 persistence in tissues, especially in healthy people-living-with-HIV-1 (PLWH) on a successful antiretroviral regimen containing second generation integrase inhibitors. Methods In the ANRS EP64 DOLUVOIR, we explore HIV-1 persistence in five accessible anatomical sites in 20 PLWH on an efficient first-line ART regimen containing dolutegravir with virological load 6 cells and 1.50 log copies of HIV-1 cell-associated-RNA/µg RNA). HIV-1 DNA is undetected in all sperm samples (n = 19) except for one (1.52 log copies HIV-1-DNA/106 cells). No difference is noted between the diversity in the four compartments. DRMs to the current regimen are found archived in compartments of six participants. Only two major DRMs to dolutegravir (G118R and R263K) are found archived in two participants. They are the results of APOBEC hypermutations. Conclusions Despite ongoing transcriptional activity, persistence of HIV-1 in deep tissues is not associated with the selection of DRMs to dolutegravir on intact proviruses. Our results suggest that the detectable transcriptional activity stems predominantly from defective proviral DNA.


  • Open Access

    Learning From Full Characterization of HIV Proviruses in People Receiving Long-Acting Cabotegravir/Rilpivirine With a History of Replication on the Antiretroviral Classes

    by Gilbert Mchantaf, Antoine Chaillon, Caroline Charre, Adeline Melard, Elise Gardiennet, Jérôme Guinard, Thierry Prazuck, Clémence Guillaume, Alice-Andrée Mariaggi, Julie Bois, et al.

    Background: To better understand factors associated with virologic response, we retrospectively characterized the HIV proviruses of 7 people with HIV who received long-acting cabotegravir/rilpivirine (CAB/RPV-LA) and were selected according to the following criteria: virologic control achieved despite a history of viral replication on 1 or both corresponding antiretroviral classes (n = 6) and virologic failure (VF) after CAB/RPV-LA initiation (n = 1). Methods: Last available blood samples before the initiation of CAB/RPV-LA were analyzed retrospectively. Near full-length HIV DNA genome haplotypes were inferred from Nanopore sequencing by the in vivo Genome Diversity Analyzer to search for archived drug resistance mutations (DRMs) and evaluate the frequency and intactness of proviruses harboring DRMs. Results: Archived DRMs including G-to-A mutations were found in samples from 3 patients who maintained virologic control. Genomes harboring DRMs were majorly in minority variants (<20%) and were defective in all cases except for 1 participant. In this participant, intact genomes with the H221Y mutation on reverse transcriptase were detected representing 11 copies per 106 peripheral blood mononuclear cells. The other mutations observed in the participants of the study resulted most likely from hypermutations. The patient with VF presented archived mutations, all associated with defects. Other factors could explain this VF. Conclusions: Our findings highlight the difficulty in interpreting the clinical significance of DRMs when detected in proviral DNA and the need to filter out hypermutated sequences. Detected DRMs could be harbored by defective archived genomes unlikely to contribute to treatment failure.


  • Top Cited Papers
    Open Access

    Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells

    by Asier Sáez-Cirión, Anne-Claire Mamez, Véronique Avettand-Fenoel, Mitja Nabergoj, Caroline Passaes, Paul Thoueille, Laurent Decosterd, Maxime Hentzien, Federico Perdomo-Celis, Maria Salgado, et al.

    HIV cure has been reported for five individuals who received allogeneic hematopoietic stem cell transplant (allo-HSCT) from CCR5Δ32 homozygous donors. In contrast, viral rebound has occurred in other people living with HIV who interrupted antiretroviral treatment after receiving allo-HSCT, mostly from wild-type CCR5 donors. Here, we report the case of a male who has achieved durable HIV remission following allo-HSCT from an unrelated HLA-matched (9/10 matching for HLA-A, -B, -C, -DRB1 and -DQB1 alleles) wild-type CCR5 donor to treat an extramedullary myeloid tumor. To date, plasma viral load has remained undetectable for 32 months after the interruption of antiretroviral treatment. Treatment with ruxolitinib has been maintained during this period to treat chronic graft versus host disease. Low levels of proviral DNA were detected sporadically post-allo-HSCT, including defective but not intact HIV DNA. No virus could be amplified in cultures of CD4 + T cells obtained post antiretroviral treatment interruption, while CD4 + T cells remained susceptible to HIV-1 infection in vitro. Decline of HIV antibodies and undetectable HIV-specific T cell responses further corroborate the absence of viral rebound after antiretroviral treatment interruption. These results suggest that HIV remission could be achieved in the context of allo-HSCT with wild-type CCR5.


  • Top Cited Papers
    Open Access

    Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

    by Caroline Passaes, Delphine Desjardins, Anaïs Chapel, Valérie Monceaux, Julien Lemaitre, Adeline Mélard, Federico Perdomo-Celis, Cyril Planchais, Maël Gourvès, Nastasia Dimant, et al.

    HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac251-infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8+ T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.


  • Open Access

    Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection

    by Pauline Trémeaux, Tiphaine Lenfant, Faroudy Boufassa, Asma Essat, Adeline Mélard, Marine Gousset, Olivier Delelis, Jean-Paul Viard, Marc Bary, Cécile Goujard, et al.